NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

May 26 2011

Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer.  

The Company previously announced 4 clinical sites for new enrollment into the ongoing trial, located in Rochester, Cleveland, Detroit and Minneapolis.  The Company has now added New York City (NYU) and Los Angeles (UCLA).  In addition, the Company is nearing completion on 4 further sites, in New Jersey, Michigan, Texas and Washington.  As a result, the Company expects to have a total of 10 clinical trial sites for new enrollment into its GBM brain cancer trial within this calendar quarter.  This will substantially exceed the Company's projections in regard to the expansion of the clinical trial this quarter.  At least 5 further clinical sites are anticipated to be added in the third quarter of this year, resulting in a total of 15 sites.

"We are gratified to have received such strong interest and cooperation from clinical centers throughout the U.S., and pleased to be ahead of schedule in completing the lengthy and complex institutional processes to make these centers operational for enrollment of additional new patients into our ongoing GBM brain cancer clinical trial," said Dr. Alton Boynton, CEO of NWBT.  

SOURCE Northwest Biotherapeutics